Effects of PDE-5 inhibitors, active surveillance among localized prostate cancer topics
Studies examining the post-prostatectomy effects of phosphodiesterase type-5 inhibitors and those discussing active surveillance are among the key papers in localized prostate cancer to be presented at this year's AUA annual meeting, according to Leonard G. Gomella, MD.
This article is part of the State of Urology 2014
Dr. GomellaStudies examining the post-prostatectomy effects of phosphodiesterase type-5 inhibitors and those discussing active surveillance are among the key papers in localized prostate cancer to be presented at this year's AUA annual meeting, according to Leonard G. Gomella, MD, professor and chairman of urology at Thomas Jefferson University, Philadelphia.
Other noteworthy research in localized prostate cancer from the meeting covers topics such as predictors of favorable urinary outcomes after treatment; comparative effectiveness of robot-assisted and open radical prostatectomy; and use of a 3-D template-guided, transrectal ultrasound-guided system to perform cognitive magnetic resonance image-targeted biopsies.
Specifically, here are Dr. Gomella's top abstract picks on localized prostate cancer from this year's meeting:
MP45-01: Predicting progression in patients followed with active surveillance for low-risk prostate cancer
Itay Sternberg
MP45-19: The clinical outcome in patients with recurrent prostate cancer after salvage extended pelvic lymph node dissection
Daniar K. Osmonov
MP46-16: Revisited: Use of proerectile medication (PDE5-I) is an independent risk factor for PSA recurrence following radical prostatectomy
Uwe Michi
MP58-11: Nightly sildenafil use after radical prostatectomy has adverse effects on urinary convalescence: Results from a randomized trial of nightly vs on-demand dosing regimens
Matthew Eric Hyndman
MP46-19: Multicenter phase II trial of perirectal hydrogel spacer application in men scheduled for dose escalation prostate radiotherapy
Gencay Hatiboglu
MP51-05: Reclassification rates are higher among African American men than white men on active surveillance
Debasish Sundi
MP51-10: Predictors of Favorable Urinary Outcomes after Prostate Cancer Treatment
Peter Chang
MP51-19: Comparative Effectiveness of Robotic-Assisted and Open Radical Prostatectomy in the “Post-Learning Curve” Era
Giorgio Gandaglia
MP51-20: Multi-parametric MRI enhances detection of significant tumor in patients on active surveillance for prostate cancer
Hamidreza Abdi
MP58-03: Intraoperative Optical Biopsy During Robotic-Assisted Radical Prostatectomy Using Confocal Laser Endomicroscopy: Initial Feasibility Study
Aristeo Lopez
MP58-04: The Use of 3-D Template-Guided, Transrectal Ultrasound–Guided System to Perform Cognitive MRI-Targeted Biopsies of the Prostate
Adam Rensing
Subscribe to Urology Times to get monthly news from the leading news source for urologists.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
